Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

Importance of Cadherins Methylation in Ovarian Cancer: a Next Generation Sequencing Approach

M. Chmelarova, I. Baranova, E. Ruszova, J. Laco, K. Hrochova, E. Dvorakova, V. Palicka,

. 2019 ; 25 (4) : 1457-1465. [pub] 20181027

Language English Country Netherlands

Document type Journal Article

Persistent link   https://www.medvik.cz/link/bmc20023654

Grant support
UHHK, 00179906 Ministerstvo Zdravotnictví Ceské Republiky
BBMRI, LM2015089 Ministerstvo Školství, Mládeže a Tělovýchovy

Epigenetic aberrations are well known to play an important role in carcinogenesis, and also have a great potential to serve as biomarkers in many types of cancers, including ovarian cancer in which sensitive and specific biomarkers and detection methods are critically needed. The aim of this study was to investigate methylation of cadherin genes CDH10, CDH13 and CDH18 in ovarian cancer tissue by comparison with control tissue. The study group consisted of 38 patients with ovarian cancer and 25 control patients. For detection of epigenetic events we used next generation sequencing, the most important data were confirmed using high-resolution melting analysis and real-time PCR. We observed significantly higher methylation in CDH13, sporadic methylation in CDH10 and loss of methylation in CDH18 in the ovarian cancer group compared with the control group. These observations suggest that changes in methylation of cadherin genes may be one of the major mechanisms associated with ovarian cancer progression. In addition, because of the high frequency of methylation of the CDH13 gene in the early stages of ovarian cancer, the analyzed CpG sites might be good targets for next study of potential ovarian cancer screening biomarkers.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc20023654
003      
CZ-PrNML
005      
20201214130732.0
007      
ta
008      
201125s2019 ne f 000 0|eng||
009      
AR
024    7_
$a 10.1007/s12253-018-0500-y $2 doi
035    __
$a (PubMed)30368729
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a ne
100    1_
$a Chmelarova, Marcela $u Institute for Clinical Biochemistry and Diagnostics, Charles University, Faculty of Medicine and University Hospital in Hradec Kralove, Hradec Kralove, Czech Republic.
245    10
$a Importance of Cadherins Methylation in Ovarian Cancer: a Next Generation Sequencing Approach / $c M. Chmelarova, I. Baranova, E. Ruszova, J. Laco, K. Hrochova, E. Dvorakova, V. Palicka,
520    9_
$a Epigenetic aberrations are well known to play an important role in carcinogenesis, and also have a great potential to serve as biomarkers in many types of cancers, including ovarian cancer in which sensitive and specific biomarkers and detection methods are critically needed. The aim of this study was to investigate methylation of cadherin genes CDH10, CDH13 and CDH18 in ovarian cancer tissue by comparison with control tissue. The study group consisted of 38 patients with ovarian cancer and 25 control patients. For detection of epigenetic events we used next generation sequencing, the most important data were confirmed using high-resolution melting analysis and real-time PCR. We observed significantly higher methylation in CDH13, sporadic methylation in CDH10 and loss of methylation in CDH18 in the ovarian cancer group compared with the control group. These observations suggest that changes in methylation of cadherin genes may be one of the major mechanisms associated with ovarian cancer progression. In addition, because of the high frequency of methylation of the CDH13 gene in the early stages of ovarian cancer, the analyzed CpG sites might be good targets for next study of potential ovarian cancer screening biomarkers.
650    _2
$a mucinózní adenokarcinom $x genetika $x patologie $7 D002288
650    _2
$a dospělí $7 D000328
650    _2
$a senioři $7 D000368
650    _2
$a senioři nad 80 let $7 D000369
650    _2
$a nádorové biomarkery $x genetika $7 D014408
650    _2
$a kadheriny $x genetika $7 D015820
650    _2
$a studie případů a kontrol $7 D016022
650    _2
$a serózní cystadenokarcinom $x genetika $x patologie $7 D018284
650    12
$a metylace DNA $7 D019175
650    _2
$a nádory endometria $x genetika $x patologie $7 D016889
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a následné studie $7 D005500
650    12
$a regulace genové exprese u nádorů $7 D015972
650    _2
$a lidé $7 D006801
650    _2
$a lidé středního věku $7 D008875
650    _2
$a nádory vaječníků $x genetika $x patologie $7 D010051
650    _2
$a prognóza $7 D011379
650    _2
$a promotorové oblasti (genetika) $7 D011401
650    _2
$a mladý dospělý $7 D055815
655    _2
$a časopisecké články $7 D016428
700    1_
$a Baranova, Ivana $u Institute for Clinical Biochemistry and Diagnostics, Charles University, Faculty of Medicine and University Hospital in Hradec Kralove, Hradec Kralove, Czech Republic. ivana.baranova@fnhk.cz.
700    1_
$a Ruszova, Ema $u Department of Clinical Genetics, University Hospital Hradec Kralove, Hradec Kralove, Czech Republic.
700    1_
$a Laco, Jan $u The Fingerland Department of Pathology, Charles University, Faculty of Medicine and University Hospital in Hradec Kralove, Hradec Kralove, Czech Republic.
700    1_
$a Hrochova, Katerina $u Institute for Clinical Biochemistry and Diagnostics, Charles University, Faculty of Medicine and University Hospital in Hradec Kralove, Hradec Kralove, Czech Republic.
700    1_
$a Dvorakova, Eva $u Department of Obstetrics and Gynecology, Charles University, Faculty of Medicine and University Hospital in Hradec Kralove, Hradec Kralove, Czech Republic.
700    1_
$a Palicka, Vladimir $u Institute for Clinical Biochemistry and Diagnostics, Charles University, Faculty of Medicine and University Hospital in Hradec Kralove, Hradec Kralove, Czech Republic.
773    0_
$w MED00180530 $t Pathology oncology research : POR $x 1532-2807 $g Roč. 25, č. 4 (2019), s. 1457-1465
856    41
$u https://pubmed.ncbi.nlm.nih.gov/30368729 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20201125 $b ABA008
991    __
$a 20201214130730 $b ABA008
999    __
$a ok $b bmc $g 1595973 $s 1114330
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2019 $b 25 $c 4 $d 1457-1465 $e 20181027 $i 1532-2807 $m Pathology oncology research $n Pathol Oncol Res $x MED00180530
GRA    __
$a UHHK, 00179906 $p Ministerstvo Zdravotnictví Ceské Republiky
GRA    __
$a BBMRI, LM2015089 $p Ministerstvo Školství, Mládeže a Tělovýchovy
LZP    __
$a Pubmed-20201125

Find record

Citation metrics

Archiving options